Dr. Stein on the KOMET-001 Trial in Relapsed/Refractory AML
In Partnership With:
Eytan M. Stein, MD, discusses the phase 1/2 KOMET-001 trial in relapsed/refractory acute myeloid leukemia.
Eytan M. Stein, MD, director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, discusses the phase 1/2 KOMET-001 trial (NCT04067336) in relapsed/refractory acute myeloid leukemia (AML).
The phase 1/2 KOMET-001 trial is a first-in-human, dose-escalation study that is evaluating the tolerability of the menin inhibitor, KO-539 (ziftomenib) in patients with relapsed/refractory AML.
Although there is limited data currently available from the trial, findings shared at a previous meeting demonstrated KO-539 elicited responses, even in patients who did not have MLL rearrangements or NPM1 mutations, Stein adds.
These initial findings prompted investigators to hypothesize whether menin inhibitors can be effective in patients with AML beyond the specific subgroup of patients with MLL rearrangements or NPM1 mutations, Stein concludes.
